Daxdilimab

DB16391InvestigationalProtein Based Therapies

Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).

Mechanism: Daxdilimab is a novel drug designed to target and bind to ILT7, which is a cell surface molecule specific to the pDC type of dendritic cells. It is currently being investigated against autoimmune diseases and COVID-19.
Curator reviewed
Code names: MEDI-7734 · VIB-7734 · WHO 11390

Resolves to

Compound

UNIICNI3N6QR71CAS2245966-28-1

Targets

P59901LILRA4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Daxdilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account